A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT ID: NCT02970318
Last Updated: 2026-02-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
310 participants
INTERVENTIONAL
2017-02-02
2027-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
NCT02337829
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
NCT02296918
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acalabrutinib (ACP-196)
Acalabrutinib (ACP-196) Monotherapy
Acalabrutinib (ACP-196)
Acalabrutinib monotherapy
Rituximab Plus Idelalisib or Bendamustine
Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
Rituximab
Rituximab in combination with idelalisib or bendamustine
Idelalisib
Idelalisib in combination with rituximab
Bendamustine
Bendamustine in combination with rituximab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rituximab
Rituximab in combination with idelalisib or bendamustine
Idelalisib
Idelalisib in combination with rituximab
Bendamustine
Bendamustine in combination with rituximab
Acalabrutinib (ACP-196)
Acalabrutinib monotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ECOG performance status of 0 to 2.
3. Diagnosis of CLL that meets published diagnostic criteria (Hallek 2008):
1. Monoclonal B-cells (either kappa or lambda light chain restricted) that are clonally co-expressing ≥ 1 B-cell marker (CD19, CD20, or CD23) and CD5.
2. Prolymphocytes may comprise ≤ 55% of blood lymphocytes.
3. Presence of ≥ 5 x 10\^9 B lymphocytes/L (5000/μL) in the peripheral blood (at any point since initial diagnosis).
4. Must have documented CD20-positive CLL.
5. Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment:
1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin \< 10 g/dL) and/or thrombocytopenia (platelets \< 100,000/μL).
2. Massive (i.e., ≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
3. Massive nodes (i.e., ≥ 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy.
4. Progressive lymphocytosis with an increase of \> 50% over a 2-month period or a LDT of \< 6 months. LDT may be obtained by linear regression extrapolation of ALC obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of \< 30 x 10\^9/L (30,000/μL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded.
5. Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy.
6. Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as ≥ 1 of the following disease-related symptoms or signs:
i. Unintentional weight loss ≥ 10% within the previous 6 months before screening.
ii. Significant fatigue (ECOG performance score 2; inability to work or perform usual activities).
iii. Fevers higher than 100.5°F or 38.0°C for ≥ 2 weeks before screening without evidence of infection.
iv. Night sweats for \> 1 month before screening without evidence of infection.
6. Meet the following laboratory parameters:
1. ANC ≥ 750 cells/μL (0.75 x 10\^9/L), or ≥ 500 cells/μL (0.50 x 10\^9/L) in subjects with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.
2. Platelet count ≥ 50,000 cells/μL (50 x 10\^9/L), or ≥ 30,000 cells/μL (30 x 10\^9/L) in subjects with documented bone marrow involvement, and without transfusion support 7 days before assessment. Subjects with transfusion-dependent thrombocytopenia are excluded. If an Investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be ≥ 75,000 cells/μL (75 x 10\^9/L).
3. Serum AST and ALT ≤ 2.0 x ULN.
4. Total bilirubin ≤ 1.5 x ULN.
5. Estimated creatinine clearance of ≥ 30 mL/min, calculated using the formula of Cockcroft and Gault \[(140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female\].
7. Must have received ≥ 1 prior systemic therapies for CLL. Note: Single-agent steroids or localized radiation are not considered a prior line of therapy. If a single-agent anti-CD20 antibody was previously administered, subjects must have received ≥ 2 doses.
8. Women who are sexually active and can bear children must agree to use highly effective forms of contraception while on the study and for 2 days after the last dose of acalabrutinib, 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5.
9. Men who are sexually active and can beget children must agree to use highly effective forms of contraception during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer. Highly effective forms of contraception are defined in Section 9.2.5.
10. Men must agree to refrain from sperm donation during the study and for 90 days after the last dose of idelalisib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer.
11. Willing and able to participate in all required evaluations and procedures in this study protocol, including swallowing capsules without difficulty.
12. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).
Exclusion Criteria
2. Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
3. Uncontrolled AIHA or ITP defined as declining hemoglobin or platelet count secondary to autoimmune destruction within the screening period or requirement for high doses of steroids (\> 20 mg daily of prednisone or equivalent).
4. Prior exposure to a BCL-2 inhibitor (e.g., venetoclax/ABT-199) or a BCR inhibitor (e.g., BTK inhibitors or PI3K inhibitors). Prior bendamustine is allowed if Investigator's choice for treatment in Arm B is idelalisib with rituximab. Bendamustine retreatment is allowed if the prior response to bendamustine lasted \> 24 months.
5. Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug.
6. Corticosteroid use \> 20 mg daily prednisone equivalent within 1 week before first dose of study drug, except as indicated for other medical conditions such as inhaled steroid for asthma, topical steroid use, or as premedication for administration of study drug or contrast. For example, subjects requiring steroids at daily doses \> 20 mg prednisone equivalent systemic exposure daily, or those who are administered steroids for leukemia control or white blood cell count lowering are excluded.
7. Prior radio- or toxin-conjugated antibody therapy.
8. Prior allogeneic stem cell transplant or prior autologous transplant within 6 months of first dose of study drug(s) or presence of graft-vs-host disease or receiving treatment for graft-vs-host disease.
9. Major surgical procedure within 30 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.
10. History of prior malignancy except for the following:
1. Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening and felt to be at low risk for recurrence by treating physician.
2. Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer.
3. Adequately treated carcinoma in situ without current evidence of disease.
11. Significant cardiovascular disease such as uncontrolled or untreated symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or QTc \> 480 msec (calculated using Fridericia's formula: QT/RR\^0.33) at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
12. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach, or extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
13. Received a live virus vaccination within 28 days of first dose of study drug.
14. Known history of infection with HIV or any uncontrolled active systemic infection (e.g., bacterial, viral, or fungal). For study sites in Germany: active infection with human immunodeficiency virus (seropositivity for HIV-1 or HIV-2 antibodies, and if positive, reactivity against the HIV-specific p24 antigen).
15. Active CMV infection (active viremia as evidenced by positive polymerase chain reaction \[PCR\] result for CMV DNA).
16. Serologic status reflecting active hepatitis B or C infection.
1. Subjects who are anti-HBc positive and who are surface antigen negative will need to have a negative PCR result before randomization. Those who are HbsAg-positive or hepatitis B PCR positive will be excluded.
2. Subjects who are hepatitis C antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis C PCR positive will be excluded.
17. Ongoing, drug-induced liver injury, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
18. History of or ongoing drug-induced pneumonitis.
19. History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis.
20. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
21. History of bleeding diathesis (e.g., hemophilia, von Willebrand disease).
22. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of first dose of study drug.
23. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
24. Requires treatment with a strong CYP3A inhibitor/inducer.
25. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.
26. Breast feeding or pregnant.
27. Concurrent participation in another therapeutic clinical trial.
28. Prothrombin time/INR or aPTT (in the absence of a Lupus anticoagulant) \> 2.0 x ULN. Exception: Subjects receiving warfarin are excluded, however, those receiving other anticoagulant therapy who have a higher INR/aPTT may be permitted to enroll to this study after discussion with the medical monitor.
29. History of confirmed progressive multifocal leukoencephalopathy (PML)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acerta Pharma BV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Brick, New Jersey, United States
Research Site
Nyack, New York, United States
Research Site
Canton, Ohio, United States
Research Site
Fort Sam Houston, Texas, United States
Research Site
Round Rock, Texas, United States
Research Site
Adelaide, , Australia
Research Site
Box Hill, , Australia
Research Site
Frankston, , Australia
Research Site
Geelong, , Australia
Research Site
Gosford, , Australia
Research Site
Hobart, , Australia
Research Site
Kogarah, , Australia
Research Site
Murdoch, , Australia
Research Site
Nedlands, , Australia
Research Site
South Brisbane, , Australia
Research Site
Woodville, , Australia
Research Site
Linz, , Austria
Research Site
Salzburg, , Austria
Research Site
Vienna, , Austria
Research Site
Vienna, , Austria
Research Site
Wels, , Austria
Research Site
Antwerp, , Belgium
Research Site
Ghent, , Belgium
Research Site
Roeselare, , Belgium
Research Site
Yvoir, , Belgium
Research Site
Pleven, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Stara Zagora, , Bulgaria
Research Site
Vratsa, , Bulgaria
Research Site
Barrie, Ontario, Canada
Research Site
Calgary, , Canada
Research Site
Montreal, , Canada
Research Site
Ottawa, , Canada
Research Site
Regina, , Canada
Research Site
Saint John, , Canada
Research Site
Toronto, , Canada
Research Site
Toronto, , Canada
Research Site
Zadar, , Croatia
Research Site
Zagreb, , Croatia
Research Site
Brno, , Czechia
Research Site
Nový Hradec Králové, , Czechia
Research Site
Olomouc, , Czechia
Research Site
Ostrava Poruba, , Czechia
Research Site
Plzen - Lochotin, , Czechia
Research Site
Prague, , Czechia
Research Site
Bordeaux, , France
Research Site
Brest, , France
Research Site
Montpellier, , France
Research Site
Nantes, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Perpignan, , France
Research Site
Provence Alpes Cote D'Azur, , France
Research Site
Rennes, , France
Research Site
Rouen, , France
Research Site
Aschaffenburg, , Germany
Research Site
Dresden, , Germany
Research Site
Mutlangen, , Germany
Research Site
München, , Germany
Research Site
Ulm, , Germany
Research Site
Hong Kong, , Hong Kong
Research Site
Pok Fu Lam, , Hong Kong
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Gyula, , Hungary
Research Site
Kaposvár, , Hungary
Research Site
Ashkelon, , Israel
Research Site
Haifa, , Israel
Research Site
Jerusalem, , Israel
Research Site
Kfar Saba, , Israel
Research Site
Nahariya, , Israel
Research Site
Petah Tikvah, , Israel
Research Site
Aviano, , Italy
Research Site
Bergamo, , Italy
Research Site
Brescia, , Italy
Research Site
Florence, , Italy
Research Site
Genova, , Italy
Research Site
Genova, , Italy
Research Site
Meldola, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Modena, , Italy
Research Site
Addington, , New Zealand
Research Site
Dunedin, , New Zealand
Research Site
Palmerston North, , New Zealand
Research Site
Tauranga, , New Zealand
Research Site
Bialystok, , Poland
Research Site
Bydgoszcz, , Poland
Research Site
Gdansk, , Poland
Research Site
Krakow, , Poland
Research Site
Lodz, , Poland
Research Site
Lublin, , Poland
Research Site
Woj. Podkarpackie, , Poland
Research Site
Novosibirsk, , Russia
Research Site
Obninsk, , Russia
Research Site
Penza, , Russia
Research Site
Ryazan, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Sochi, , Russia
Research Site
Tula, , Russia
Research Site
Volgograd, , Russia
Research Site
Yaroslavl, , Russia
Research Site
Yekaterinburg, , Russia
Research Site
SGP, , Singapore
Research Site
SGP, , Singapore
Research Site
SGP, , Singapore
Research Site
Bratislava, , Slovakia
Research Site
Košice, , Slovakia
Research Site
Busan, , South Korea
Research Site
Daegu, , South Korea
Research Site
Donggu, , South Korea
Research Site
Gyeonggi-do, , South Korea
Research Site
Incheon, , South Korea
Research Site
Jeonju, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Badalona, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Majadahonda, , Spain
Research Site
Salamanca, , Spain
Research Site
Santander, , Spain
Research Site
Valencia, , Spain
Research Site
Gothenburg, , Sweden
Research Site
Luleå, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Hualien City, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Cherkasy, , Ukraine
Research Site
Dnipropetrovsk, , Ukraine
Research Site
Ivano-Frankivsk, , Ukraine
Research Site
Khmelnytsky, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Zhytomyr, , Ukraine
Research Site
Birmingham, , United Kingdom
Research Site
Cambridge, , United Kingdom
Research Site
Canterbury, , United Kingdom
Research Site
Leicester, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Maidstone, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Southampton, , United Kingdom
Research Site
Wolverhampton, , United Kingdom
Research Site
Chandler, Arizona, United States
Research Site
Oxnard, California, United States
Research Site
Athens, Georgia, United States
Research Site
Joliet, Illinois, United States
Research Site
Cedar Rapids, Iowa, United States
Research Site
Mount Sterling, Kentucky, United States
Research Site
Saint Cloud, Minnesota, United States
Research Site
Lincoln, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Eek D, Ivanescu C, Corredoira L, Meyers O, Cella D. Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia. J Patient Rep Outcomes. 2021 Mar 11;5(1):27. doi: 10.1186/s41687-021-00294-1.
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-004454-17
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ACE-CL-309
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.